Therapy with hyperimmune plasma from recovered COVID19 patients has been suggested as a possible therapeutic approach. Intravenous immunoglobulins (IVIg) may harbour some protective effect. Patients undergoing IVIg or SCIg chronic treatments may have a reduced risk of contracting COVID-19 infection compared to patients receiving other immune therapies or no therapy.
Background. Intravenous immunoglobulin (IVIg) treatment partially replaces antibody defects and modulates innate and adaptive immune cells in patients with primary antibody deficiencies.
Materials and methods. This study was focused on the evaluation of the effects of in vivo IVIg administration on neutrophils from patients with common variable immune disorders (CVID). We examined polymorphonuclear neutrophil (PMN) phagocytosis, PMN oxidative burst, release of neutrophil elastase, serum level of interleukin-8 and PMN expression of CXCR1, CD11c and CD66b.
© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma
